X4 Pharmaceuticals initiates Phase II/III trial of X4P-001-LD to treat WHIM syndrome

Clinical stage bio-technology firm X4 Pharmaceuticals has initiated its Phase II/III clinical trial of X4P-001-LD with the first patient dosing to treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news